Phase 2 Trial of Tau Antibody RO7105705 Recruiting Patients with Moderate Alzheimer’s
A Phase 2 trial is enrolling patients with moderate Alzheimer’s to test an investigational antibody known as RO7105705 that targets the Tau protein. The Genentech-sponsored multicenter, randomized study (NCT03828747) intends to assess the efficacy, safety, and pharmacological profile of RO7105705. The company plans to recruit 260…